Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIRECURE: Early ART for HIV Functional Cure
NCT02588820Phase 3Unknown
- Start
- Apr 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tenofovir disoproxil fumarate, emtricitabine, dolutegravir, darunavir, ritonavir and 3 more in human immunodeficiency virus type 1 infection (HIV-1). Primary endpoint: Proportion of patients with undetectable viral reservoir at 12 months. Status: unknown.
02
Drugs
tenofovir disoproxil fumarateemtricitabinedolutegravirdarunavirritonavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02588820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588820.